ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity.
 PMID: 10458616       1999       Journal of acquired immune deficiency syndromes (1999)
Abstract: An HIV strain encoding the M184V mutation was susceptible to the combination of MA and abacavir.


  Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.
 PMID: 10482597       1999       Journal of virology
Abstract: In replication kinetics assays, mutant Leu74Val replicated slower than the mutant Met184Val.
Abstract: The replication kinetics and RT processivity of the mutant with the Leu74Val mutation were compared to those of a lamivudine-selected mutant Met184Val.
Abstract: These observations provide biochemical evidence of decreased processivity to support the decrease in replication fitness observed with the Leu74Val or Met184Val mutations.


  Adefovir dipivoxil.
 PMID: 10493275       1999       Drugs
Abstract: The drug was most effective in patients with baseline isolates containing the M184V lamivudine resistance mutation according to data from a virological substudy of a large placebo-controlled trial.


  Reduced antiretroviral drug susceptibility among patients with primary HIV infection.
 PMID: 10501117       1999       JAMA
Abstract: Population-based sequence analysis of these 3 samples identified multidrug-resistance mutations in reverse transcriptase (M184V, T215Y, K219K/R) and protease (L101/V, K20R, M361, M46I, G48V, L63P, A71T, V771, V82T, 184V, L90M) in the 2 latter patient samples, along with numerous polymorphisms.


  Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy.
 PMID: 10502270       1999       Journal of medical virology
Abstract: However, four of five women in the dual therapy arm had the M184V mutation in the reverse transcriptase gene associated with decreased susceptibility to lamivudine at delivery.


  In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues.
 PMID: 10508028       1999       Antimicrobial agents and chemotherapy
Abstract: However, in the presence of QYL-685 (4 microM), HIV-1(M184I) and HIV-1(M184V) showed greater fitness than HIV-1(wt).
Abstract: These data may provide structural and virological relevance with regard to the emergence of M184I and M184V substitutions in HIV-1.
Abstract: Two infectious clones, HIV-1(M184I) and HIV-1(M184V), were resistant to QYL-685, QYL-609, and 3TC, confirming that the M184I mutation was responsible for the observed resistance.


  Drug resistance mutations among HIV-1 strains from antiretroviral-naive patients in Martinique, French West Indies.
 PMID: 10634203       1999       Journal of acquired immune deficiency syndromes (1999)
Abstract: Mutant strains L74V (didanosine [ddI] and dideoxycytidine [ddC]) were detected in 3 patients and M184V (lamivudine/ddI/ddC) in 4 patients.


  Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the delta lamivudine roll-over study.
 PMID: 10682151       1999       Antiviral therapy
Abstract: CONCLUSIONS: M184V-mediated zidovudine resensitization of HIV-1 is transient in most patients who are given zidovudine/lamivudine combination therapy when zidovudine resistance has already emerged.
Abstract: Zidovudine resensitization (related to acquisition of the M184V mutation) was transient, with evolution towards dual resistance to zidovudine and lamivudine in 20 of the 29 patients.


  In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.
 PMID: 10682153       1999       Antiviral therapy
Abstract: Interestingly, lamivudine-resistant viruses expressing the M184V RT mutation showed wild-type to slightly increased susceptibility to PMPA in vitro and addition of the M184V mutation to HIV with the K65R mutation resulted in reversion to wild-type susceptibility for PMPA.


  Selection and characterization of HIV-1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine (dOTC).
 PMID: 12731757       1999       Antiviral therapy
Abstract: Clinical isolates of HIV-1 resistant to lamivudine and containing the M184V substitution also displayed low-level resistance to both (-) and (+) dOTC when grown in CBMC.
Abstract: Cloning and sequencing of the complete reverse transcriptase (RT) coding region of these variants identified the M1841 mutation and further selection with virus containing the M1841 substitution led to the appearance of an M184V mutation.
Abstract: Finally, cell-free RT assays were performed in the presence of either (-) dOTC triphosphate, (+) dOTC triphosphate, or the triphosphate of a racemic mixture of (+) and (-) dOTC with wild-type and mutated M184V-containing recombinant RT.



Browser Board

 Co-occurred Entities




   Filtrator